Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pramipexole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 5/20 | 0.97 |
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 0.97 |
| ▸ | DRD4 known ✓ | P21917 | 2/20 | 0.97 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | HRH2 | P25021 | 2/20 | 0.97 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.97 |
| ▸ | HTR1A | P08908 | 1/20 | 0.97 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.97 |
| ▸ | HTR1B | P28222 | 1/20 | 0.97 |
| ▸ | HTR2A | P28223 | 1/20 | 0.97 |
| ▸ | HTR7 | P34969 | 1/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.97 |
| ▸ | HRH1 | P35367 | 1/20 | 0.97 |
| ▸ | HTR2B | P41595 | 1/20 | 0.97 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.97 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.97 |
| ▸ | SCN3A | Q9NY46 | 5/20 | 0.55 |
| ▸ | SCN4A | P35499 | 4/20 | 0.55 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pramipexole SCHEMBL4099920 | 1.00 | ADRA2A (1.00) | ADRA2ADRD3DRD2DRD4HRH2 | |
| Pramipexole SCHEMBL42113 | 1.00 | ADRA2A (1.00) | ADRA2ADRD3DRD2DRD4HRH2 | |
| Pramipexole SCHEMBL408536 | 1.00 | ADRA2A (1.00) | ADRA2ADRD3DRD2DRD4HRH2 | |
| Dexpramipexole SCHEMBL910147 | 1.00 | ADRA2A (1.00) | ADRA2ADRD3DRD2DRD4HRH2 | |
| Pramipexole SCHEMBL2995942 | 1.00 | ADRA2A (1.00) | ADRA2ADRD3DRD2DRD4HRH2 | |
| Pramipexole SCHEMBL4440257 | 1.00 | ADRA2A (1.00) | ADRA2ADRD3DRD2DRD4HRH2 | |
| Pramipexole SCHEMBL28716749 | 1.00 | ADRA2A (1.00) | ADRA2ADRD3DRD2DRD4HRH2 | |
| Pramipexole SCHEMBL743891 | 0.99 | DRD3 (1.00) | ADRA2ADRD3DRD2DRD4HRH2 | |
| Pramipexole SCHEMBL2048695 | 0.99 | DRD3 (1.00) | ADRA2ADRD3DRD2DRD4HRH2 | |
| Pramipexole SCHEMBL7106169 | 0.99 | ADRA2A (0.97) | ADRA2ADRD3DRD2DRD4HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140100372-A1 | SYNTHESIS OF CHIRALLY PURIFIED SUBSTITUTED BENZOTHIAZOLE DIAMINES | KNOPP NEUROSCIENCES, INC. (US) | 2014-04-10 | — | — | US | claimed |
| US-7868029-B2 | Process for the preparation of 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazoles from cyclohexanes and cyclohexanones as intermediates | GENERICS [UK] LIMITED (GB) | 2011-01-11 | — | — | US | claimed |
| EP-2137171-A2 | SYNTHESIS OF CHIRALLY PURIFIED SUBSTITUTED BENZOTHIAZOLE DIAMINES | Knopp Neurosciences, Inc. (US) | 2009-12-30 | — | — | EP | claimed |
| EP-1542981-B1 | PROCESS FOR THE PREPARATION OF 2-AMINO-4,5,6,7-TETRAHYDRO-6-AMINOBENZOTHIAZOLES FROM CYCLOHEXANES AND CYCLOHEXANONES AS INTERMEDIATES | GENERICS UK LTD (GB) | 2009-07-22 | — | — | EP | claimed |
| WO-2008113056-A2 | SYNTHESIS OF CHIRALLY PURIFIED SUBSTITUTED BENZOTHIAZOLE DIAMINES | KNOPP NEUROSCIENCES, INC. (US) | 2008-09-18 | — | — | WO | claimed |
| US-20080227985-A1 | SYNTHESIS OF CHIRALLY PURIFIED SUBSTITUTED BENZOTHIAZOLES | KNOPP NEUROSCIENCES, INC. (US) | 2008-09-18 | — | — | US | claimed |
| US-6667329-B1 | Immediate effect; greater activity | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-12-23 | — | — | US | claimed |
| EP-1093369-B1 | AGENT WITH AN ANTIDEPRESSIVE EFFECT COMPRISING PRAMIPEXOLE AND SERTRALINE | BOEHRINGER INGELHEIM PHARMA (DE) | 2002-11-27 | — | — | EP | claimed |
| US-6255329-B1 | PSYCHOLOGICAL DRUGS; SYNERGISTIC MIXTURE | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-07-03 | — | — | US | claimed |
| EP-1093369-A2 | AGENTS WITH AN ANTIDEPRESSIVE EFFECT | Boehringer Ingelheim Pharma KG (DE) | 2001-04-25 | — | — | EP | claimed |
| WO-2000006162-A1 | AGENTS WITH ANTIDEPRESSANT ACTION, CONTAINING PRAMIPEXOL AND A FURTHER ANTIDEPRESSANT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-02-10 | — | — | WO | claimed |
| WO-2000002542-A2 | AGENTS WITH AN ANTIDEPRESSIVE EFFECT CONTAINING PRAMIPEXOL AND AN ADDITIONAL ANTIDEPRESSANT DRUG | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-01-20 | — | — | WO | claimed |
| US-20250352653-A1 | NEURON TARGETED 2-DEOXYGLUCOSE DENDRIMER FOR IMAGING AND TREATMENT OF NEUROLOGICAL DISEASES | UNIV WASHINGTON STATE (US) | 2025-11-20 | — | — | US | disclosed |
| CN-112279817-B | Preparation method of high-purity pramipexole dihydrochloride | 珠海润都制药股份有限公司 | 2023-04-28 | — | — | CN | disclosed |
| CN-114075128-A | Preparation method of pramipexole degradation impurity | 北京康派森医药科技有限公司 | 2022-02-22 | — | — | CN | disclosed |
| CN-112279817-A | Preparation method of high-purity pramipexole dihydrochloride | 珠海润都制药股份有限公司 | 2021-01-29 | — | — | CN | disclosed |
| US-4886812-A | REGULATING DOPAMINE CONCENTRATION; PARKINSON DISEASE, HYPOTENSIVE AGENT, SCHIZOPHRENIA | DR. KARL THOMAE GMBH (DE) | 1989-12-12 | — | — | US | disclosed |
| US-4843086-A | HYPOTENSIVE AGENTS, SCHIZOPHRENIA, PARKINSON'S DISEASE | BOEHRINGER INGELHEIM KG (DE) | 1989-06-27 | — | — | US | disclosed |
| US-4731374-A | PARKINSON*S DISEASE | DR. KARL THOMAE GMBH (DE) | 1988-03-15 | — | — | US | disclosed |
| EP-0186087-A1 | Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs | Dr. Karl Thomae GmbH (DE) | 1986-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140100372-A1 | SYNTHESIS OF CHIRALLY PURIFIED SUBSTITUTED BENZOTHIAZOLE DIAMINES | SAT1, AADAT, DDC | DRD3 525/4885DRD2 259/4885DRD4 35/4885 |
| US-20080227985-A1 | SYNTHESIS OF CHIRALLY PURIFIED SUBSTITUTED BENZOTHIAZOLES | AADAT, BCAT2, BCAT1 | DRD3 536/4885DRD2 310/4885DRD4 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.